Another week, another review, or even reviews. The latest HTA Review announcement confirmed new review processes on discount rates, comparators, and co-dependent pathways, which have all been repeatedly examined over the past decade. These endless bureaucratic reviews are about squeezing the life out of actual reform, like juice from a lemon. Meanwhile, patients keep paying the price for this Faustian pact, and for some, that means dying.
Latest Video
New Stories
-
OncoSil completes first production run at new Sydney manufacturing facility
December 17, 2025 - - Australian Biotech -
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 - - Australian Biotech -
Novartis names new Country President following leadership transition
December 16, 2025 - - Latest News -
Mayne Pharma opens expanded manufacturing facility after termination of takeover
December 16, 2025 - - Latest News -
Budget update includes impact of listings, but generally not much else
December 16, 2025 - - Latest News -
The UK reconfirms the direct impact of the transatlantic shift in medicine pricing
December 16, 2025 - - Latest News -
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News
